You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

NATEGLINIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Nateglinide

A generic version of NATEGLINIDE was approved as nateglinide by DR REDDYS LABS LTD on September 9th, 2009.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NATEGLINIDE?
  • What are the global sales for NATEGLINIDE?
  • What is Average Wholesale Price for NATEGLINIDE?
Drug patent expirations by year for NATEGLINIDE
Drug Prices for NATEGLINIDE

See drug prices for NATEGLINIDE

Recent Clinical Trials for NATEGLINIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ministry of Health, KuwaitPhase 4
Dasman Diabetes InstitutePhase 4
Kuwait UniversityPhase 4

See all NATEGLINIDE clinical trials

Pharmacology for NATEGLINIDE
Drug ClassGlinide
Mechanism of ActionPotassium Channel Antagonists
Paragraph IV (Patent) Challenges for NATEGLINIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
STARLIX Tablets nateglinide 60 mg and 120 mg 021204 2004-12-22

US Patents and Regulatory Information for NATEGLINIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alvogen NATEGLINIDE nateglinide TABLET;ORAL 205055-001 Dec 11, 2015 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising NATEGLINIDE nateglinide TABLET;ORAL 205544-001 Jun 18, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cadila Pharms Ltd NATEGLINIDE nateglinide TABLET;ORAL 206432-002 Apr 19, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for NATEGLINIDE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Limited Starlix nateglinide EMEA/H/C/000335
Nateglinide is indicated for combination therapy with metformin in type-2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.
Withdrawn no no no 2001-04-03
Novartis Europharm Ltd. Trazec nateglinide EMEA/H/C/000383
Nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.
Withdrawn no no no 2001-04-03
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.